IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 76-100 out of 1352.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 > >>

Public Release: 19-May-2016
JAMA Oncology
Can a healthy lifestyle prevent cancer?
A large proportion of cancer cases and deaths among U.S. individuals who are white might be prevented if people quit smoking, avoided heavy drinking, maintained a BMI between 18.5 and 27.5, and got moderate weekly exercise for at least 150 minutes or vigorous exercise for at least 75 minutes, according to a new study published online by JAMA Oncology.

Contact: Todd Datz
tdatz@hsph.harvard.edu
617-432-8413
The JAMA Network Journals

Public Release: 19-May-2016
European Society of Human Genetics Conference 2016
Mouse studies hold promise for a simple treatment for an aggressive gastric tumor
Patients with aggressive neuroendocrine tumours (NETs) have limited treatment options and there are few oncologists who are specialised in this relatively rare disease. Normally a total gastrectomy (removal of the stomach) is employed in these cases, with a subsequent dramatic reduction in the quality of life for patients. Now researchers have identified a mutation in the human ATP4a gene that is involved in the gastric acid secretion regulation and has been identified as responsible of an aggressive form of inherited, early-onset gastric NET.
Spanish Center for Biomedical Network Research on Rare Diseases, European Commission, Spanish Government

Contact: Mary Rice
mary.rice@riceconseil.eu
European Society of Human Genetics

Public Release: 19-May-2016
Cell Reports
Researchers identify super-oncogenic protein that promotes development of melanoma
A study led by scientists at the Sanford Burnham Prebys Medical Discovery Institute has identified a malicious form of ATF2, a protein that drives the formation of melanoma.
National Institutes of Health, Melanoma Research Foundation, Hervey Family Fund at the San Diego Foundation

Contact: Susan Gammon
sgammon@sbpdiscovery.org
858-795-5012
Sanford-Burnham Prebys Medical Discovery Institute

Public Release: 19-May-2016
Journal of Radiation Oncology
Combining radiation with immunotherapy showing promise against melanoma
Combining radiation treatments with a new generation of immunotherapies is showing promise as a one-two-punch against melanoma, Loyola Medicine researchers report in the Journal of Radiation Oncology.

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System

Public Release: 19-May-2016
Cancer Epidemiology, Biomarkers & Prevention
Intake of dietary fat in adolescence associated with breast density
Consuming high amounts of saturated fat or low amounts of mono- and polyunsaturated fats as an adolescent was associated with higher breast density in young adulthood. Breast density is a risk factor for breast cancer.
NIH/National Cancer Institute, American Institute for Cancer Research, NIH/National Heart, Lung, and Blood Institute

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research

Public Release: 19-May-2016
Cell Reports
Malignancy-associated gene network regulated by an RNA binding protein
The RNA binding protein IGF2BP3 is normally active in fetal tissue and undetectable in most adult tissue. But production of the protein is reactivated in many types of aggressive cancer, and it is associated with poor prognosis in both solid tumors and leukemias. New findings from UC Santa Cruz point toward a possible mechanism by which this protein drives metastasis.
National Institutes of Health, Santa Cruz Cancer Benefit Group, University of California, California Institute for Regenerative Medicine

Contact: Tim Stephens
stephens@ucsc.edu
831-459-4352
University of California - Santa Cruz

Public Release: 19-May-2016
JAMA Oncology
Higher survival rate for overweight colorectal cancer patients than normal-weight patients
Overweight colorectal cancer patients were 55 percent less likely to die from their cancer than normal-weight patients who have the disease, according to a new Kaiser Permanente study published today in JAMA Oncology.
NIH/National Cancer Institute

Contact: Heather Platisha
heather.platisha@creation.io
415-262-5992
Kaiser Permanente

Public Release: 19-May-2016
Molecular Cell
'Sunscreen' gene may help protect against skin cancer
A new USC-led study identified a 'sunscreen' gene that may help stave off skin cancer. Researchers found that the 'UV radiation Resistance Associated Gene' is a tumor suppressor for skin cancer, which is the most common form of cancer in the United States. People who have the mutated UV-resistant gene or low levels of the UV-resistant gene may be at higher risk of melanoma or other skin cancers, especially if they go sunbathing or tanning frequently.
Margaret Early Trustee Foundation, American Cancer Society, National Institutes of Health, National Research Foundation of Korea

Contact: Zen Vuong
zvuong@usc.edu
213-300-1381
University of Southern California

Public Release: 19-May-2016
Cancer Epidemiology, Biomarkers & Prevention
High saturated-fat, low unsaturated-fat diet in adolescence tied to higher breast density
Adolescent girls whose diet is higher in saturated fats and lower in healthier unsaturated fats have higher breast density in early adulthood, which may potentially increase their risk for breast cancer later in life, according to a new study led by researchers at the University of Maryland School of Medicine. The research was published online today in Cancer Epidemiology, Biomarkers & Prevention.
American Institute for Cancer Research, NIH/National Cancer Institute, NIH/National Heart, Lung, and Blood Institute

Contact: Karen Warmkessel
kwarmkessel@umm.edu
410-328-8919
University of Maryland Medical Center

Public Release: 19-May-2016
Cancer Cell
High levels of protein p62 predict liver cancer recurrence
Researchers at University of California San Diego School of Medicine and Sanford Burnham Prebys Medical Discovery Institute have discovered that high levels of the protein p62 in human liver samples are strongly associated with cancer recurrence and reduced patient survival. In mice, they also found that p62 is required for liver cancer to form.
National Institutes of Health, Superfund Basic Research Program, American Association for Study of Liver Diseases, American Liver Foundation

Contact: Heather Buschman
hbuschman@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 19-May-2016
Oncotarget
Vitamin E a potential biomarker for development of brain tumors
Researchers at Umeå University in Sweden and the Cancer Registry of Norway have studied possible causes behind the development of brain tumors. The results, published in the journal Oncotarget, show differences in expression of certain molecules known as metabolites when comparing healthy individuals with people who would eventually develop brain tumors. The greatest difference were found when looking at vitamin E.

Contact: Daniel Harju
daniel.harju@umu.se
46-725-522-918
Umea University

Public Release: 19-May-2016
Science
Fighting cancer with the help of someone else's immune cells
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might. Their proof of principle study is published in the journal Science on May 19.

Contact: Nadine Boke
n.boke@ni.nl
31-205-126-284
Netherlands Cancer Institute

Public Release: 19-May-2016
JCI Insight
Identification of a chemotherapy resistance factor in breast cancer patients
In this issue of JCI Insight, a research team led by Mercedes Rincon at the University of Vermont identified low expression of methylation-controlled J protein (MCJ) as a marker of poor response to chemotherapy.
Terry Fox Fund for Cancer Research, National Institutes of Health, Lake Champlain Cancer Center Research Organization

Contact: Corinne Williams
press_releases@the-jci.org
JCI Journals

Public Release: 19-May-2016
ecancermedicalscience
The science of the condolence letter
Many don't know this, but some doctors write condolence letters to the bereaved families of lost patients. This practice has rarely been studied or discussed, particularly in the UK, where cultural practices surrounding grief are often private. A small survey asked doctors whether condolence letters should become part of official policy.

Contact: Audrey Nailor
audrey@ecancer.org
117-403-3093
ecancermedicalscience

Public Release: 19-May-2016
Aging
Artificial Neural Networks guess patient's age with surprising accuracy
Deep learning methods are propagating into biomarker discovery and aging research. An Ensemble of Deep Neural Networks achieved 83.5 percent epsilon-accuracy r = 0.91 with R2 = 0.82 and MAE = 5.55 years when guessing chronological age outperforming many other available markers of aging This system may provide insight into the biological age of the person if the person 'looks' older or younger to Aging.AI then his/her chronological age

Contact: Qingsong Zhu
zhu@insilicomedicine.com
443-451-7212
InSilico Medicine, Inc.

Public Release: 18-May-2016
Science Translational Medicine
New drug combination shows promise for resistant leukemia
Patients with acute myeloid leukemia (AML) can look forward to the development of new therapies following the discovery by Walter and Eliza Hall Institute researchers of a new way to kill cells that are dangerously multiplying. A process known as apoptosis (programmed cell death) -- which is a natural and necessary response to keep the proliferation of human cells in check -- is interrupted in cancers, including AML, leading to unchecked cell growth.
Leukemia & Lymphoma Society, National Health and Medical Research Council, Association pour le Recherche contre le Cancer fellowship, Australian Cancer Research Foundation,Victorian State Government Operational Infrastructure Support

Contact: Ebru Yaman
ebru.yaman@wehi.edu.au
042-803-4089
Walter and Eliza Hall Institute

Public Release: 18-May-2016
Nature
Staying a step ahead of cancer
Howard Hughes Medical Institute scientists have designed a potential cancer therapy that uses a unique strategy to block mTOR, a molecule that helps drive the growth of many tumors. In animal experiments, the drug reduces the size of tumors that are resistant to earlier-generation mTOR inhibitors.

Contact: Jim Keeley
keeleyj@hhmi.org
301-215-8858
Howard Hughes Medical Institute

Public Release: 18-May-2016
Science Translational Medicine
Two-pronged attack on chemotherapy-resistant leukemia cells
Acute lymphoblastic leukemia is the most common type of childhood cancer in Switzerland. Despite intensive chemotherapy, one fifth of the patients suffer a relapse, which usually goes hand in hand with a poor prognosis. Researchers from the University of Zurich and the Children's Hospital Zurich have now found a way to kill off resistant leukemia cells: via necroptosis.
Childhood Cancer Research Foundation Switzerland, Empiris Foundation, Panacée Foundation, Swiss Cancer Research Foundation, Clinical Research Priority Program, University of Zurich's Forschungskredit, and others

Contact: Beat Bornhauser
beat.bornhauser@kispi.uzh.ch
41-446-348-817
University of Zurich

Public Release: 18-May-2016
Brain Connectivity
Altered brain connectivity may explain cognitive impairment in pediatric leukemia survivors
The neurotoxic effects of chemotherapeutic drugs on the developing brains of young patients with acute lymphoblastic leukemia (ALL) may impair their cognitive functioning by disrupting the formation of neural networks that connect brain regions and transfer information. A study showing reduced connectome organization in the brains of ALL survivors is published in Brain Connectivity.

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 18-May-2016
Oncotarget
Biomarker may predict endometrial cancer recurrences
New research from the lab of Martina Bazzaro, Ph.D., of the Masonic Cancer Center, University of Minnesota and Department of Obstetrics, Gynecology, and Women's Health, suggests the deubiquitinating enzyme USP14 as a promising biomarker for identifying risk of recurrence in endometrial cancer patients.

Contact: Caroline Marin
crmarin@umn.edu
612-624-5680
University of Minnesota Academic Health Center

Public Release: 18-May-2016
International Journal of Radiation Oncology • Biology • Physics
Conventional radiation therapy may not protect healthy brain cells
A new study shows that repeated radiation therapy used to target tumors in the brain may not be as safe to healthy brain cells as previously assumed. The findings, which appear in the International Journal of Radiation Oncology, Biology, Physics, show that the treatment also kills important support cells in the brain and may cause as much, if not more damage, than single dose radiation therapy.
URMC Countermeasures Against Radation Program, NIH/National Insitute of Allergy and Infectious Diseases, Toxicology Training Program, Schmitt Program in Integrative Neuroscience

Contact: Mark Michaud
mark_michaud@urmc.rochester.edu
585-273-4790
University of Rochester Medical Center

Public Release: 18-May-2016
Oncotarget
Scientists uncover novel therapeutic targets and candidate biomarkers in childhood cancers
Brazilian scientists have obtained evidence suggesting that neurotrophins, which are well-known signaling molecules in normal brain development and function, may be useful biomarkers and therapeutic targets in childhood cancers. Blockade of the receptors that mediate neurotrophin signaling, namely TrkA and TrkB, have been shown to produce anticancer effects in both Ewing sarcoma and medulloblastoma. Additionally, levels of a neurotrophin have been associated with leukemia prognosis.
The Children's Cancer Institute, Rafael Koff Acordi Project at ICI, National Council for Scientific and Technological Development, Brazilian Ministry of Health, Coordination for the Improvement of Higher Education Personnel

Contact: Dr. Rafael Roesler
rafael.roesler@pq.cnpq.br
55-513-359-7616
Write Science Right

Public Release: 18-May-2016
Oncotarget
Sylvester researchers develop novel, non-toxic approach to treating variety of cancers
A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers. The treatment approach is based on a combination therapy of the sugar 2-Deoxy-D-glucose (2-DG) and fenofibrate, a well-studied cholesterol medication.

Contact: Patrick Bartosch
patrick.bartosch@med.miami.edu
305-243-8219
University of Miami Miller School of Medicine

Public Release: 17-May-2016
Journal of Neuroscience
Cisplatin may cause more permanent hearing loss in people with Cockayne syndrome
'Our studies of a mouse model of Cockayne syndrome are the first to point to the importance of ongoing DNA repair in protecting the sensitive sensory hair cells of the inner ear from such environmental stress,' the senior author said. 'We show that the same mutations, causing Cockayne syndrome in humans, make the sensory hair cells of mice hypersensitive to DNA damage caused by cisplatin chemotherapy.'
National Institutes of Health, Sidgmore Family Foundation

Contact: Zen Vuong
zvuong@usc.edu
213-300-1381
University of Southern California

Public Release: 17-May-2016
International Journal of Cardiology
Simple screening test can predict heart failure severity
It is now recognized that sarcopenia, defined as the loss of muscle mass and strength, is related to heart failure. Recent research from Kumamoto University, Japan has shown that heart failure severity could be diagnosed by using a simple sarcopenia screening test that assesses age, grip strength and calf circumference.
Japan Health Foundation, St. Luke's International University Center for Clinical Epidemiology

Contact: J. Sanderson, N. Fukuda
research-coordinator@jimu.kumamoto-u.ac.jp
Kumamoto University

Showing releases 76-100 out of 1352.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 > >>

  Search News Releases

     

 

EurekAlert!